IRIDEX (NASDAQ: IRIX) grows glaucoma sales as Q2 revenue drops
Rhea-AI Filing Summary
IRIDEX CORP (IRIX) reported second quarter 2026 revenue of $12.6 million, down 7% from $13.6 million a year earlier, as weaker retina sales offset growth in glaucoma products. Retina product revenue fell to $6.5 million from $8.0 million, while Cyclo G6 product family revenue rose 19% to $3.9 million, driven by higher probe volumes.
Gross margin was stable at 34.2% versus 34.5% last year. Operating expenses declined 5% to $5.3 million on lower general and administrative costs, but net loss widened to $1.3 million (–$0.07 per share) from $1.0 million (–$0.06). Adjusted EBITDA moved to a loss of $0.4 million from a small profit. The company was operating cash-flow positive in the quarter and ended July 4, 2026 with $4.7 million in cash and cash equivalents.
IRIDEX reaffirmed full-year 2026 revenue guidance of $51–$53 million and expects fiscal 2026 adjusted operating expenses of $19.0–$19.5 million. Management highlighted ongoing cost-transformation efforts, including shifting production to lower-cost contract manufacturers and relocating headquarters, which are intended to support long-term profitability.
Positive
- Cyclo G6 glaucoma revenue grew 19% year-over-year to $3.9 million, with probe units rising from 13,100 to 17,700, showing strong demand in the glaucoma segment.
- Company was operating cash flow positive in Q2 2026 while still investing in business transformation initiatives.
- IRIDEX reaffirmed full-year 2026 revenue guidance of $51–$53 million, indicating confidence despite near-term retina headwinds.
Negative
- Retina product revenue declined from $8.0 million to $6.5 million, an almost 19% drop, driven by international disruptions and regulatory-related factors.
- Quarterly net loss increased to $1.3 million (–$0.07 per share) from $1.0 million (–$0.06), reflecting weaker overall revenue.
- Adjusted EBITDA deteriorated from a small profit of $21 thousand to an adjusted EBITDA loss of $0.4 million in Q2 2026.
8-K Event Classification
Key Figures
Key Terms
Adjusted EBITDA financial
operating cash flow positive financial
deferred revenue financial
Convertible note payable financial
MicroPulse technology medical
Earnings Snapshot
Reaffirmed full-year 2026 revenue guidance of $51–$53 million and expects adjusted operating expenses of $19.0–$19.5 million.
FAQ
How did IRIDEX (IRIX) perform financially in Q2 2026?
How did IRIDEX’s glaucoma (Cyclo G6) business perform in Q2 2026?
What happened to IRIDEX (IRIX) retina revenue in Q2 2026?
What is IRIDEX’s full-year 2026 revenue outlook?
What were IRIDEX’s margins and cash position in Q2 2026?
How did IRIDEX’s adjusted EBITDA change in Q2 2026?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES Washington, D.C. 20549 |
||||
|
||||
FORM CURRENT REPORT |
||||
|
||||
PURSUANT TO SECTION 13 OR 15(d) OF THE |
||||
|
|
|||
(Date of Report (date of earliest event reported) |
||||
|
||||
(Exact name of registrant as specified in its charter) |
||||
|
||||
(State or other jurisdiction of |
(Commission File Number) |
(I.R.S. Employer |
||
(Address of principal executive offices, including zip code) |
||||
|
||||
( |
||||
(Registrant’s telephone number, including area code) |
||||
(Former name or former address, if changed since last report) |
||||
|
||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): |
||||
|
||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
||||
Emerging growth company |
||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
||||
Securities registered pursuant to Section 12(b) of the Act:
Title of Class |
|
Trading Symbol |
|
Name of Exchange on Which Registered |
|
|
Item 2.02. Results of Operations and Financial Condition.
On August 18, 2026, IRIDEX Corporation issued a press release discussing its financial results for its second fiscal quarter ended July 4, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
|
|
(d) |
Exhibits |
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press Release dated August 18, 2026. |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
IRIDEX CORPORATION |
|
|
|
|
|
By: |
|
/s/ Romeo R. Dizon |
|
|
|
Romeo R. Dizon |
|
|
|
Chief Financial Officer |
|
|
|
|
Date: August 18, 2026 |
|
|
|
-3-
Exhibit 99.1
Iridex Reports Second Quarter 2026 Financial Results
MOUNTAIN VIEW, Calif., August 18, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the treatment of glaucoma and retinal diseases, today reported financial results for the second quarter ended July 4, 2026.
Second Quarter 2026 Financial Highlights
“Our second quarter results were highlighted by the continued momentum in our glaucoma business and operating positive cash flows,” said Patrick Mercer, President and CEO of Iridex. “Cyclo G6 probe volume increased by approximately 35%, with this lifting G6 product family revenue by 19% compared to the prior year. This strong performance on the glaucoma side of the business, together with our continued success in controlling costs resulted in positive cash flow in the quarter. Our strong performance in glaucoma was offset by a weaker quarter in retina, due primarily to disruptions impacting the Middle East and reduced sell through in China. As we advance international regulatory approvals, we expect to improve overall retina performance driven by our flagship Pascal platform.”
“We are continuing to make significant progress transforming our business, including the transfer of production to lower cost contract manufacturers and relocation of our headquarters to a lower cost facility. We expect this restructuring of the business will help us to achieve sustained long-term profitability” Mr. Mercer continued.
Second Quarter 2026 Financial Results
Total revenue for the three months ended July 4, 2026 was $12.6 million, representing a decline of 7% compared to the second quarter of 2025. The decrease in revenue was primarily driven by lower retina product sales, partially offset by continued growth in glaucoma probe sales. Total retina product revenue was $6.5 million compared to $8.0 million in the prior year period. The decline was isolated to our retina portfolio and driven entirely by temporary, external headwinds—including international commercial transitions and regulatory approval related factors. Total product revenue from the Cyclo G6 product family was $3.9 million, representing growth of 19% compared to $3.3 million in the prior year period, driven by strong Cyclo G6 probe demand. Other revenue was $2.2 million, essentially flat compared to $2.2 million in the prior year period.
Gross margin in the second quarter of 2026 was 34.2%, relatively flat compared to a gross margin of 34.5% in the prior year period.
Operating expenses were $5.3 million in the second quarter of 2026, a decrease of $0.3 million, or 5%, compared to $5.6 million in the second quarter of 2025. The decrease was primarily attributable to lower general and administrative expenses, as a result of the administrative function transfer initiative announced in prior periods.
Net loss was $1.3 million, or $0.07 per share, for the second quarter of 2026, compared to a net loss of $1.0 million, or $0.06 per share, in the same period of the prior year.
Non-GAAP adjusted EBITDA loss for the second quarter of 2026 was $0.4 million, compared to non-GAAP adjusted EBITDA of $21 thousand for the second quarter of 2025.
Cash and cash equivalents as of July 4, 2026 were $4.7 million, an increase of $0.1 million compared to April 4, 2026.
2026 Financial Outlook
The Company is reaffirming its annual revenue guidance for the full year 2026 of between $51 million and $53 million. Updating on cash flows for the full year, the Company plans to use more of its working capital to procure additional inventory in anticipation of transitioning to its new headquarters and production facility. The additional inventory will better secure international product supply chains and protect distributor revenue streams against the potential of interruptions related to obtaining required international regulatory approvals following the Company’s relocating its headquarters later this year.
The Company continues to expect fiscal year 2026 adjusted operating expenses, which exclude depreciation and amortization and stock-based compensation, to be in the range of $19 million to $19.5 million.
Webcast and Conference Call Information
Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by accessing the live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com or by dialing +1-646-307-1963 from the US or +1-800-715-9871 internationally and providing Conference ID: 9329659.
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, which include capital equipment and consumable probes for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers the therapeutic benefits of laser treatment while minimizing tissue damage, offering a safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse®, Iridex PASCAL®, IQ 532®, IQ 577®, OcuLight® TX, Cyclo G6®, MicroPulse P3®, G-Probe®, and G-Probe Illuminate® are a registered trademark of Iridex Corporation, Inc. in the United States, Europe, and other jurisdictions.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning commercial trends, market adoption and expansion, expectations regarding profitability, demand for and utilization of the Company's products, financial results and forecasts and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks further described in the “Risk Factors” section of Iridex’s most recent Annual Report on Form 10-K, as well as in Iridex’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
Use of Non-GAAP Financial Information
This press release contains financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). Management evaluates and makes operating decisions using various performance measures. In addition to Iridex’s GAAP results, we consider Adjusted EBITDA. This
non-GAAP result should not be considered as an alternative to net income, net cash provided by operating activities, or any other performance measure derived in accordance with GAAP. We present this non-GAAP result because management considers it to be an important supplemental measure of Iridex’s performance and refers to such measures when analyzing Iridex’s strategy and operations.
In calculating the above non-GAAP result: Adjusted EBITDA is defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as excluding certain other non-GAAP adjustments. Adjusted EBITDA exclude from their GAAP equivalents items listed below:
Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational or non-cash expenses involving stock compensation plans or other items.
A detailed reconciliation between Iridex’s non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release as well as in Iridex’s other reports filed with or furnished to the SEC.
Investor Relations Contact
Philip Taylor
Gilmartin Group
investors@iridex.com
IRIDEX Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
July 4, 2026 |
|
|
June 28, 2025 |
|
|
July 4, 2026 |
|
|
June 28, 2025 |
|
||||
Total revenues |
|
$ |
12,566 |
|
|
$ |
13,571 |
|
|
$ |
24,365 |
|
|
$ |
25,467 |
|
Cost of revenues |
|
|
8,270 |
|
|
|
8,889 |
|
|
|
15,328 |
|
|
|
15,730 |
|
Gross profit |
|
|
4,296 |
|
|
|
4,682 |
|
|
|
9,037 |
|
|
|
9,737 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
936 |
|
|
|
871 |
|
|
|
1,841 |
|
|
|
1,747 |
|
Sales and marketing |
|
|
2,547 |
|
|
|
2,535 |
|
|
|
5,084 |
|
|
|
4,988 |
|
General and administrative |
|
|
1,842 |
|
|
|
2,216 |
|
|
|
3,465 |
|
|
|
4,147 |
|
Total operating expenses |
|
|
5,325 |
|
|
|
5,622 |
|
|
|
10,390 |
|
|
|
10,882 |
|
Loss from operations |
|
|
(1,029 |
) |
|
|
(940 |
) |
|
|
(1,353 |
) |
|
|
(1,145 |
) |
Other expense, net |
|
|
(167 |
) |
|
|
(33 |
) |
|
|
(309 |
) |
|
|
(1,502 |
) |
Loss from operations before provision for income taxes |
|
|
(1,196 |
) |
|
|
(973 |
) |
|
|
(1,662 |
) |
|
|
(2,647 |
) |
Provision for income taxes |
|
|
70 |
|
|
|
21 |
|
|
|
128 |
|
|
|
33 |
|
Net loss |
|
$ |
(1,266 |
) |
|
$ |
(994 |
) |
|
$ |
(1,790 |
) |
|
$ |
(2,680 |
) |
Net loss per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
(0.07 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.10 |
) |
|
$ |
(0.16 |
) |
Diluted |
|
$ |
(0.07 |
) |
|
$ |
(0.06 |
) |
|
$ |
(0.10 |
) |
|
$ |
(0.16 |
) |
Weighted average shares used in computing net loss per common share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
17,418 |
|
|
|
16,793 |
|
|
|
17,376 |
|
|
|
16,760 |
|
Diluted |
|
|
17,418 |
|
|
|
16,793 |
|
|
|
17,376 |
|
|
|
16,760 |
|
IRIDEX Corporation
Condensed Consolidated Balance Sheets
(In thousands)
|
|
July 4, 2026 |
|
|
January 3, 2026 |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
4,680 |
|
|
$ |
6,028 |
|
Accounts receivable, net |
|
|
7,089 |
|
|
|
9,545 |
|
Inventories |
|
|
9,752 |
|
|
|
7,877 |
|
Prepaid expenses and other current assets |
|
|
2,437 |
|
|
|
1,802 |
|
Total current assets |
|
|
23,958 |
|
|
|
25,252 |
|
Property and equipment, net |
|
|
182 |
|
|
|
58 |
|
Intangible assets, net |
|
|
825 |
|
|
|
984 |
|
Goodwill |
|
|
965 |
|
|
|
965 |
|
Operating lease right-of-use assets, net |
|
|
220 |
|
|
|
768 |
|
Other long-term assets |
|
|
1,108 |
|
|
|
1,124 |
|
Total assets |
|
$ |
27,258 |
|
|
$ |
29,151 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
6,809 |
|
|
$ |
5,502 |
|
Accrued compensation |
|
|
1,634 |
|
|
|
2,340 |
|
Accrued expenses |
|
|
760 |
|
|
|
608 |
|
Other current liabilities |
|
|
1,683 |
|
|
|
1,899 |
|
Deferred revenue, current |
|
|
2,146 |
|
|
|
2,160 |
|
Operating lease liabilities, current |
|
|
141 |
|
|
|
699 |
|
Total current liabilities |
|
|
13,173 |
|
|
|
13,208 |
|
Long-term liabilities: |
|
|
|
|
|
|
||
Deferred revenue |
|
|
6,078 |
|
|
|
6,801 |
|
Operating lease liabilities |
|
|
77 |
|
|
|
98 |
|
Convertible note payable |
|
|
3,795 |
|
|
|
3,735 |
|
Other long-term liabilities |
|
|
496 |
|
|
|
387 |
|
Total liabilities |
|
|
23,619 |
|
|
|
24,229 |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Series B convertible preferred stock |
|
|
6,000 |
|
|
|
6,000 |
|
Common stock |
|
|
174 |
|
|
|
174 |
|
Additional paid-in capital |
|
|
91,712 |
|
|
|
91,208 |
|
Accumulated other comprehensive loss |
|
|
(11 |
) |
|
|
(14 |
) |
Accumulated deficit |
|
|
(94,236 |
) |
|
|
(92,446 |
) |
Total stockholders’ equity |
|
|
3,639 |
|
|
|
4,922 |
|
Total liabilities and stockholders’ equity |
|
$ |
27,258 |
|
|
$ |
29,151 |
|
|
|
|
|
|
|
|
||
IRIDEX Corporation
Reconciliation of GAAP Net Loss to Adjusted EBITDA
(In thousands)
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
July 4, 2026 |
|
|
June 28, 2025 |
|
|
July 4, 2026 |
|
|
June 28, 2025 |
|
||||
Reconciliation of GAAP net loss to Adjusted EBITDA(a) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
GAAP net loss |
|
$ |
(1,266 |
) |
|
$ |
(994 |
) |
|
$ |
(1,790 |
) |
|
$ |
(2,680 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income |
|
|
(6 |
) |
|
|
(14 |
) |
|
|
(12 |
) |
|
|
(21 |
) |
Other expense |
|
|
173 |
|
|
|
48 |
|
|
|
321 |
|
|
|
1,524 |
|
Provision for income taxes |
|
|
70 |
|
|
|
21 |
|
|
|
128 |
|
|
|
33 |
|
Nasdaq listing compliance |
|
|
- |
|
|
|
152 |
|
|
|
- |
|
|
|
152 |
|
Reconvention of shareholders' meeting expenses |
|
|
62 |
|
|
|
- |
|
|
|
62 |
|
|
|
- |
|
Legal settlement expenses |
|
|
40 |
|
|
|
- |
|
|
|
40 |
|
|
|
- |
|
Depreciation and amortization |
|
|
362 |
|
|
|
378 |
|
|
|
734 |
|
|
|
759 |
|
Stock-based compensation |
|
|
212 |
|
|
|
257 |
|
|
|
423 |
|
|
|
470 |
|
Severance related expense (for head count reduction) |
|
|
- |
|
|
|
173 |
|
|
|
- |
|
|
|
199 |
|
Adjusted EBITDA |
|
$ |
(353 |
) |
|
$ |
21 |
|
|
$ |
(94 |
) |
|
$ |
436 |
|
(a)Defined as earnings before interest income and expense, taxes, depreciation, amortization, and share-based compensation, as well as certain non-GAAP adjustments.